Floatz logo

Edoxaban

Vascular Brain Injury

University of AlbertaSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Vascular Brain Injury cohort.

Asset / SponsorPhaseRating
Tenecteplase
Beijing Tiantan Hospital
Phase 1CC
Carbon Dioxide
Imperial College London
N/AD

Same molecule, other indications

Edoxaban is also rated in:

atrial fibrillationDormant
A
Indicative ·
83 / 100
View asset →
intracerebral hemorrhageDormant
BBB
Indicative ·
78 / 100
View asset →
EmbolismDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →